Quintrio
Home

SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

Lucid Diagnostics Inc. Common Stock

LUCD

Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.

Last trade $0.3794
Day change -$0.0184 (-4.63%)
Day range $0.37 – $0.406
Volume 1,515,194
Market cap $77M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$77.88M
Price / earnings
—
Price / book
13.13×
Price / sales
14.32×
EV / sales
14.2×
EV / EBITDA
-1.53×

Profitability

Earnings per share
-$0.31
Return on assets
-220%
Return on equity
-1,033.14%
Dividend yield
0%

Liquidity and leverage

Debt / equity
2.92×
Current ratio
1.2×
Quick ratio
1.18×
Cash ratio
0.83×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$51.83M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for LUCD, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$1.2M$1.47M$1.26M$1.5M$1.21M$1.16M$828K$1.2M
Cost of revenue$1.4M$1.45M$1.63M$1.86M$1.7M$1.56M$1.55M$2.15M
Gross profit-$201K$29K-$369K-$356K-$486K-$400K-$723K-$948K
Selling, general and administrative$10.79M$11.53M$10.43M$11.83M$9.9M$9.62M$10.23M$9.87M
Research and development$1.18M$1.19M$1.21M$1.72M$1.27M$1.26M$1.43M$1.45M
Total operating expenses$12.08M$12.83M$11.75M$13.66M$11.27M$10.98M$11.76M$11.43M
Operating income-$12.28M-$12.8M-$12.11M-$14.01M-$11.76M-$11.38M-$12.49M-$12.38M
Interest expense-$1K-$4K-$6K-$6K-$2K-$6K-$9K-$7K
Income before taxes-$6.68M-$11.69M-$13.91M-$16.27M-$10.4M-$4.44M-$26.91M-$11.54M
Income taxes$0$0$0$0$0$0$0$0
Net income-$6.68M-$11.69M-$13.91M-$16.27M-$10.4M-$4.44M-$26.91M-$11.54M
Net income attributable to common shareholders-$6.68M-$14.72M-$23.63M-$16.27M-$10.4M-$7.89M-$36.02M-$11.54M
EBITDA-$12.05M-$12.58M-$11.89M-$14.04M-$11.54M-$11.16M-$12.27M-$12.4M
Basic earnings per share-$0.03-$0.08-$0.17-$0.12-$0.10-$0.08-$0.52-$0.20
Diluted earnings per share-$0.03-$0.08-$0.17-$0.12-$0.10-$0.08-$0.52-$0.20

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Orthofix (OFIX) Surpasses Q3 Earnings Estimates

Orthofix reported Q3 2026 earnings of $0.18 per share, beating consensus estimates of $0.11 by 63.64%, but revenues of $207.8 million missed expectations by 1.25%. The stock has underperformed the market significantly, down 48.1% year-to-date versus the S&P 500's 7.8% gain. With a Zacks Rank #3 (Hold) rating, the stock is expected to perform in line with the market near-term.

Zacks Investment Research

Mettler-Toledo (MTD) Surpasses Q3 Earnings and Revenue Estimates

Mettler-Toledo reported Q3 2026 earnings of $12.57 per share, beating consensus estimates of $12.11, with revenues of $1.09 billion exceeding expectations by 2.28%. The company has outperformed the market by 23.6% year-to-date. However, the stock received a Zacks Rank #3 (Hold) rating due to mixed estimate revisions, suggesting near-term performance in line with the market.

GlobeNewswire Inc.

Oil Above $100 Puts Penny Stocks in Focus

With U.S. crude above $100 per barrel, investors are turning to smaller companies with emerging technologies. Kraig Biocraft Laboratories shipped its first commercial spider silk order, Hyperscale Data reaffirmed 2027 revenue guidance of $300-350 million, Lucid Diagnostics began receiving Medicare payments for its EsoGuard test, and 22nd Century Group reported 66% quarterly revenue growth with improving profitability metrics.

Benzinga

Lucid Diagnostics to Hold Fourth Quarter and Full Year 2025 Business Update Conference Call and Webcast on March 26, 2026

Lucid Diagnostics Inc. (NASDAQ:LUCD), a cancer prevention medical diagnostics company and subsidiary of PAVmed Inc., announced it will host a business update conference call and webcast on March 26, 2026, at 8:30 AM ET. CEO Lishan Aklog will provide a business update and discuss operations and growth strategy, while CFO Dennis McGrath will discuss fourth quarter 2025 financial results.

Benzinga

PAVmed Announces Reverse Stock Split

PAVmed Inc. announced a 1-for-30 reverse stock split effective January 2, 2026, to comply with Nasdaq's $1.00 minimum bid price requirement. The split was approved by stockholders on December 5, 2025, and authorized shares will be reduced from 250 million to 25 million. The company's stock will continue trading under symbol PAVM on Nasdaq Capital Market.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.